Dimension Capital has closed an $800 million third fund, adding $300 million to its war chest, a 60 percent increase over its $500 million second vehicle. TechCrunch reported the fund close on July 21, 2026, noting the firm has grown rapidly since its late-2022 founding. The raise gives Dimension greater capacity to lead larger early and growth rounds and to follow on in later stages across the science-plus-compute sector. The partners say they will deploy Dimension III into additional companies across that spectrum over the next few months.

The immediate effect is a larger dedicated pool of venture capital for the science-plus-compute sector, because Dimension III totals $800 million, up from $500 million for Fund II, TechCrunch reported on July 21, 2026.

The headline is numeric and simple: Dimension III adds $300 million to the firm’s available capital, a 60 percent jump from Fund II announced just 18 months earlier. That pace of fund growth shows how quickly limited partners are willing to increase bets on the intersection of AI, software and biology. The firm only launched in late 2022, so the size and speed of the raise mark a steep ascent in a short window.

Dimension Capital was founded by former Lux Capital partners Zavain Dar and Adam Goulburn, together with Nan Li from Obvious Ventures. The firm positions itself as a specialist investor focused on companies that digitize scientific workflows, apply machine learning to biology, or build compute infrastructure for lab research. Its mandate covers AI-enabled drug discovery platforms, lab automation, machine learning infrastructure for science, and enterprise software that digitizes biology.

TechCrunch cited several portfolio examples that map the thesis to real outcomes: Chai Discovery, New Limit, Modal Labs and a strategic equity position in Anthropic that arrived after Anthropic acquired Dimension portfolio company Coefficient Bio in spring 2026 for a reported $400 million. Dimension co-led a $30 million seed round in Chai Discovery in 2024; Chai then raised $400 million at a $3.8 billion valuation in July 2026. Dimension also backed New Limit at Series A in January 2025, and New Limit completed a Series C at a $3.1 billion valuation in July 2026. Those financings and the Coefficient Bio exit provide near-term validation of the firm’s focus.

The partners say the adoption of heavy compute in scientific workflows has compressed timelines they once expected would take years into months. Dimension has written checks across models and stages, from single-digit-million seed investments to financings above $50 million, and it has co-led rounds with major venture firms in deals that reached multibillion-dollar valuations quickly. The larger fund increases Dimension’s capacity to lead bigger rounds and to support companies through follow-on financings, which raises the odds of larger exits and strategic M&A.

The fund close is a vote of confidence from limited partners that the convergence of AI and biology is more than a niche theme. With an $800 million vehicle, Dimension can compete for ownership in platform vendors that sell tools to pharma as well as product companies developing medicines. That dual mandate matters because platform companies tend to need less capital per program but broader distribution, while product companies need deeper follow-on funding to reach clinical milestones. A larger specialised fund makes both paths easier to finance from a single firm.

Related Articles

Dimension says it will deploy Dimension III into more companies over the next few months. Investors will judge the fund by concrete outcomes, starting with the reported $400 million Coefficient Bio acquisition.

This article was created with AI assistance.